drugset / Trial / NCT01319188
Ranibizumab and the Risk of Arterial Thromboembolic Events
Phase 4
Terminated
380 enrolled
Ural State Medical University
De Haar Research Foundation · collabUral Institute of Cardiology · collab
RandomizedParallel-groupDouble-blindScreening
Summary
The investigators assume that ranibizumab might be dangerous in patients with history of coronary artery disease or cerebrovascular events. The main objective of study is to reveal contraindications for ranibizumab prescription in patients with history of coronary artery disease and cerebrovascular events. Moreover, an association between management with ranibizumab and ATE rate in healthy above 50 years old persons is a concern of great interest as well.
Timeline
- Start
- 2010-06
- Primary completion
- 2012-10
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |